Table 1.
Characteristics of patients with non-severe relapse
| RTX | CYC/AZA | ALL | |
|---|---|---|---|
| N=23 | N=21 | N=44 | |
| Male | 12 (52%) | 9 (43%) | 21 (48%) |
| PR3-ANCA positive | 18 (78%) | 18 (86%) | 36 (82%) |
| GPA | 20 (87%) | 20 (95%) | 40 (91%) |
| Relapsing disease at study entry | 15 (65%) | 13 (62%) | 28 (64%) |
| Mean time to first non-severe relapse (range, months)* | 7.7 (1.8–15.1) | 7.3 (2.4–16.9) | 7.5 (1.8–16.9) |
| Reached remission before relapse | 20 (87%) | 20 (95%) | 40 (91%) |
| BVAS/WG at relapse | 1.8 | 1.6 | 1.7 |
| Off prednisone at relapse | 14 (61%) | 14 (67%) | 28 (64%) |
| Median prednisone dose at relapse if dose > 0 mg/day (range) | 5.0 (2.5–20) | 5.0 (2.5–15) | 5.0 (2.5–20) |
| Organ involvement | |||
| Constitutional features† | 18 (78%) | 11 (52%) | 29 (66%) |
| Cutaneous involvement | 2 (9%) | 1 (5%) | 3 (7%) |
| Mucous membranes and eyes | 2 (9%) | 5 (24%) | 7 (16%) |
| Mouth ulcers | 1 (4%) | 0 (0%) | 1 (2%) |
| Conjunctivitis/episcleritis | 0 (0%) | 5 (24%) | 5 (11%) |
| Other | 1 (4%) | 0 (0%) | 1 (2%) |
| Ear, nose and throat | 7 (30%) | 4 (19%) | 11 (25%) |
| Bloody nasal discharge | 3 (13%) | 2 (10%) | 5 (11%) |
| Sinus involvement | 2 (9%) | 2 (10%) | 4 (9%) |
| Other | 2 (9%) | 1 (5%) | 3 (7%) |
| Pulmonary involvement | 5 (22%) | 3 (14%) | 8 (18%) |
| Nodules/cavities | 2 (9%) | 1 (5%) | 3 (7%) |
| Endobronchial involvement | 0 (0%) | 2 (10%) | 2 (5%) |
| Other | 3 (13%) | 1 (5%) | 4 (9%) |
| Renal involvement - hematuria | 1 (4%) | 3 (14%) | 4 (9%) |
| Other minor items | 2 (9%) | 0 (0%) | 2 (5%) |
*
Of the four patients who flared before reaching remission, those flares occurred at 1.8, 2.4 and 3.9 months (in two patients) after study entry.
†
fevers, arthritis/arthralgias